drugset / Trial / NCT00833040
A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 (Sufentanil NanoTab) Compared to Placebo in the Treatment of Cancer Breakthrough Pain
RandomizedCrossoverQuadruple-blindTreatment
Summary
The purpose of this research study was to evaluate ARX-F02 (Sufentanil NanoTab) versus placebo ("sugar" pill or inactive substance) in the management of breakthrough pain in cancer patients.
Timeline
- Start
- 2009-04
- Primary completion
- 2010-03
- Completion
- 2010-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sufentanil | Other / unclassified | 20 ug | Other |
| Subject | Sufentanil | Other / unclassified | 30 ug | Other |
| Subject | Sufentanil | Other / unclassified | 40 ug | Other |
| Subject | Sufentanil | Other / unclassified | 60 ug | Other |
| Subject | Sufentanil | Other / unclassified | 80 ug | Other |